FF EAI Robotics Ecosystem Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Poirier Michael S., was filed 22 Jun 2022.
FF EAI Robotics Ecosystem Inc.: what insiders have been doing
FF EAI Robotics Ecosystem Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of FF EAI Robotics Ecosystem Inc. in twelve months, the latest record being from 22 June 2022.
The full history, which starts in 2015, counts 25 purchases against 2 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- -83.8%Entry 291.00 · Close at T+365 47.00
- -83.6%Entry 290.00 · Close at T+365 47.50
- -68.4%Entry 635.00 · Close at T+365 200.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
- 30,000 shares@ US$0.57100.0% of flowCommon StockSEC:0001493152-22-017505:0Canonical exit: 20 Sept 2022 (T+90)
- 30,000 shares@ US$0.62100.0% of flowCommon StockSEC:0001493152-22-016857:0Canonical exit: 12 Sept 2022 (T+90)
- 4,000 shares@ US$1.2211.7% of flowCommon StockSEC:0001493152-21-020787:1Canonical exit: 17 Nov 2021 (T+90)
- 4,000 shares@ US$1.23100.0% of flowCommon StockSEC:0001493152-21-020787:0Canonical exit: 17 Nov 2021 (T+90)
- 4,500 shares@ US$2.0329.8% of flowCommon StockSEC:0001493152-21-009781:0Canonical exit: 25 Jul 2021 (T+90)
- 11,005 shares@ US$1.8050.4% of flowCommon StockSEC:0001493152-21-009359:0Canonical exit: 19 Jul 2021 (T+90)
- 2,700 shares@ US$1.86100.0% of flowCommon StockSEC:0001493152-21-009073:0Canonical exit: 15 Jul 2021 (T+90)
- 4,000 shares@ US$2.93530.6% of flowCommon StockSEC:0001493152-20-024516:0Canonical exit: 29 Mar 2021 (T+90)
- 1,400 shares@ US$3.54913.3% of flowCommon StockSEC:0001493152-20-022337:0Canonical exit: 18 Feb 2021 (T+90)
- 4,600 shares@ US$3.46242.7% of flowCommon StockSEC:0001493152-20-022337:1Canonical exit: 21 Feb 2021 (T+90)
- 9,841 sharesCommon StockSEC:0001493152-20-009958:0
- 169,192 sharesCommon StockSEC:0001493152-20-009959:0
- 76,923 shares0Common StockSEC:0001382963-20-000084:0
- 38,461 shares0Common StockSEC:0001382963-20-000084:1
- 500,000 shares@ US$0.2258.6% of flowCommon StockSEC:0001209191-20-019349:0
- 18,750 shares@ US$0.3756100.0% of flowCommon StockSEC:0001382963-20-000032:0
- 18,750 shares@ US$0.3756100.0% of flowCommon StockSEC:0001382963-20-000030:0
- 500,000 shares@ US$0.1541.4% of flowCommon StockSEC:0001209191-20-013620:0
- 19,751 shares@ US$2.0464.5% of flowCommon StockSEC:0001382963-18-000125:0Canonical exit: 15 Nov 2018 (T+90)
- 5,000,000 sharesCommon StockSEC:0001382963-17-000168:0Canonical exit: 1 Jan 2018 (T+90)
- 187,500 sharesCommon StockSEC:0001382963-17-000170:0Canonical exit: 1 Jan 2018 (T+90)
- 5,000,000 sharesCommon StockSEC:0001382963-17-000166:0Canonical exit: 1 Jan 2018 (T+90)
- 187,500 sharesCommon StockSEC:0001382963-17-000172:0Canonical exit: 1 Jan 2018 (T+90)
- 18,000 shares@ US$0.619715.4% of flowCommon StockSEC:0001382963-17-000085:0Canonical exit: 16 Aug 2017 (T+90)
- 13,000 shares@ US$0.615910.6% of flowCommon StockSEC:0001382963-17-000080:0Canonical exit: 9 Aug 2017 (T+90)
25 of 41 declarations
About FF EAI Robotics Ecosystem Inc.
Qualigen Therapeutics, Inc. is a U.S.-listed biotechnology company traded on NASDAQ in the United States, with a corporate base historically associated with Carlsbad, California. For French-speaking investors, it is best understood as a small-cap, high-risk healthcare story whose value proposition has shifted over time from diagnostics toward oncology-focused drug development. The company’s current structure dates to a reverse recapitalization completed on May 22, 2020, when Ritter Pharmaceuticals was renamed Qualigen Therapeutics. The operating and technological heritage, however, comes from Qualigen, Inc., which was originally founded in 1996 in Minnesota before later being reincorporated in Delaware. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1460702/000164117225017212/form10-k.htm?utm_source=openai))
Qualigen’s business model has historically had two pillars: rapid diagnostics and therapeutics. Its best-known legacy asset is the FastPack® platform, a point-of-care quantitative immunoassay system designed for decentralized clinical settings. On the therapeutic side, the company has focused on oncology programs, including QN-247 and RAS-F, and later identified QN-302 as a lead program, described in SEC filings as a G-quadruplex-selective transcription inhibitor. Importantly, the company disclosed that its former FastPack diagnostics business was sold in July 2023 to Chembio Diagnostics, which materially changed the profile of the business and left Qualigen more concentrated on research and development rather than commercial diagnostics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1460702/000149315222008431/form10-k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Qualigen operates in the crowded oncology biotech space, where success depends on clinical validation, regulatory progress, and access to capital. It does not compete as a diversified commercial pharmaceutical group; instead, it is a development-stage company whose equity case is driven by the optionality of its pipeline and by potential milestone events from preclinical or clinical data. That makes the stock highly sensitive to funding needs, dilution risk, and execution risk, which is typical for emerging biotech names. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001460702/000149315226013434/form10-k.htm?utm_source=openai))
Recent corporate milestones underline this transition. The sale of the FastPack business in 2023, the reverse stock split in 2022, and recent SEC reporting for the year ended December 31, 2025 indicating no trials were performed during that year all point to a company in repositioning mode. For investors tracking SEC Form 4 insider transactions, this matters because insider buys or sells can be informative, but they should be interpreted against the backdrop of a very small, volatile issuer with a strategy still centered on pipeline development rather than operating scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1460702/000149315224013400/form10-k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
